Valuation: Faeth Therapeutics, Inc.

Market Cap 727M 637M 589M 541M 1.02B 70.08B 1.04B 7.04B 2.76B 34.29B 2.73B 2.67B 118B P/E 2026 *
-0.38x
P/E 2027 * -1.72x
Enterprise Value 727M 637M 589M 541M 1.02B 70.08B 1.04B 7.04B 2.76B 34.29B 2.73B 2.67B 118B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.55%
Yield 2026 *
-
Yield 2027 * -
1 day+8.97%
1 week-22.04%
Current month+12.76%
1 month+58.19%
3 months-7.54%
6 months+170.02%
Current year+164.20%
1 week 23.82
Extreme 23.815
35.66
1 month 17.5
Extreme 17.5
37.9
Current year 8.37
Extreme 8.37
37.9
1 year 6.32
Extreme 6.325
37.9
3 years 5
Extreme 5
38.8
5 years 5
Extreme 5
247.4
10 years 5
Extreme 5
530
Manager TitleAgeSince
Chief Executive Officer 40 2026-06-12
Director of Finance/CFO 45 2026-06-12
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 62 2024-12-31
Director/Board Member 72 2014-12-31
Director/Board Member 51 2021-07-29
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Buy

Chief Financial Officer

5,000 0.0194%
6/26/26 Buy

Chief Financial Officer

6,250 0.0242%
6/23/26 Buy

Chief Financial Officer

9,230 0.0358%
Change 5-day change 1-year change 3-year change Capi.($)
+8.97%-22.04%+259.57%+15.53% 667M
+0.21%-1.34%+53.17%+60.65% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
-1.20%-7.43%+4.35%+406.96% 23.48B
+0.74%+0.73%-16.23%-15.55% 23.13B
+3.46%+0.79%+34.01%-4.47% 19.36B
-1.18%-1.15%+30.12%-32.02% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%-2.42%+29.70%+663.64% 14.83B
-0.70%-1.72%+24.87%+184.19% 14.06B
Average +1.76%-5.04%+63.39%+164.66% 23.42B
Weighted average by Cap. +1.50%-2.42%+42.08%+140.49%

Financials

2026 *2027 *
Net sales - -
Net income -241M -211M -195M -179M -339M -23.2B -344M -2.33B -913M -11.35B -903M -884M -39.1B -121M -106M -98.14M -90.21M -171M -11.68B -173M -1.17B -460M -5.71B -455M -445M -19.68B
Net Debt - -
Logo Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.
Employees
29
Date Price Change Volume
26-07-20 US$28.19 +8.97% 122,882
26-07-17 US$25.87 -0.27% 98,700
26-07-16 US$25.94 -17.57% 662,909
26-07-15 US$31.47 -4.98% 568,208
26-07-14 US$33.12 -0.72% 233,759
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
28.19USD
Average target price
54.00USD
Spread / Average Target
+91.56%

Quarterly revenue - Rate of surprise